Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer
| Autor: | Natsuo Tomita, Yuji Ogura, Yutaro Koide, Hiroshi Tanaka, Jun Furusawa, Norihito Soga, Takeshi Kodira, Hiroyuki Tachibana |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_specialty Multivariate analysis medicine.drug_class medicine.medical_treatment Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Japan Internal medicine medicine Humans Cumulative incidence 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over Genitourinary system business.industry Prostatic Neoplasms Cancer Androgen Antagonists General Medicine Middle Aged Androgen medicine.disease Radiation therapy Treatment Outcome 030220 oncology & carcinogenesis Radiotherapy Intensity-Modulated business Radiotherapy Image-Guided |
| Zdroj: | Asia-Pacific Journal of Clinical Oncology. 15:18-25 |
| ISSN: | 1743-7555 |
| DOI: | 10.1111/ajco.13097 |
| Popis: | AIM To investigate 10-year outcomes of high-dose image-guided intensity-modulated radiation therapy (IG-IMRT) combined with long-term androgen deprivation therapy (ADT) for Japanese patients with nonmetastatic prostate cancer. METHODS A retrospective analysis was performed on 208 Japanese patients with T1-4N0M0 prostate cancer, who underwent definitive IG-IMRT from 2006 to 2010 at our single institution. The median dose was 78 Gy (74-78) and median ADT time was 32 months (6-151). The risk stratification followed the National Comprehensive Cancer Network criteria. A biochemical relapse was defined as nadir plus 2.0 ng/mL. Toxicity was scored with the Radiation Therapy Oncology Group morbidity scale. RESULTS The median follow-up time was 102 months. For low-, intermediate-, high-, and very-high-risk groups, the 10-year biochemical disease-free survival rates were 100%, 84%, 90%, and 72%, respectively (P = 0.008); clinical relapse-free survival rates were 100%, 100%, 100%, and 81%, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text